These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 11173045)

  • 1. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.
    Buttgereit F; Burmester GR; Simon LS
    Am J Med; 2001 Feb; 110 Suppl 3A():13S-9S. PubMed ID: 11173045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
    Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
    South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
    Bannwarth B
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B79-84. PubMed ID: 11449148
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective inhibitors of COX-2--are they safe for the stomach?
    Giercksky KE; Haglund U; Rask-Madsen J
    Scand J Gastroenterol; 2000 Nov; 35(11):1121-4. PubMed ID: 11145280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cyclooxygenase-2-specific inhibitors.
    Cannon GW; Breedveld FC
    Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2-Selective NSAIDs: new and improved?
    Lichtenstein DR; Wolfe MM
    JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
    [No Abstract]   [Full Text] [Related]  

  • 11. NSAIDs: gastroprotection or selective COX-2 inhibitor?
    Dickman A; Ellershaw J
    Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events and COX-2 inhibitors.
    Fleming M
    JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract]   [Full Text] [Related]  

  • 13. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
    Micklewright R; Lane S; Linley W; McQuade C; Thompson F; Maskrey N
    Aliment Pharmacol Ther; 2003 Feb; 17(3):321-32. PubMed ID: 12562444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase inhibition: between the devil and the deep blue sea.
    Hawkey CJ
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III25-30. PubMed ID: 11953329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.
    Perazella MA; Tray K
    Am J Med; 2001 Jul; 111(1):64-7. PubMed ID: 11448662
    [No Abstract]   [Full Text] [Related]  

  • 20. Considerations for the safe prescribing and use of COX-2-specific inhibitors.
    Med J Aust; 2002 Apr; 176(7):328-31. PubMed ID: 12013326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.